GLP3: A Research Overview of the Triple-Receptor Agonist Peptide (Retatrutide / LY3437943)

GLP3 is a synthetic 39-amino-acid peptide reference compound registered under CAS number 2381089-83-2. In the scientific literature the same molecule is designated retatrutide (development code LY3437943). Its molecular formula is C221H343N51O64 with an average molecular weight of approximately 4731.4 g/mol, and it is supplied as a lyophilized white powder specified at greater than or equal to 99% purity in a 20 mg vial.

What distinguishes GLP3 from earlier incretin-class research peptides is that it was engineered as a single peptide chain that engages three different class B G-protein-coupled receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). The discovery and characterization paper describes it as a peptide with balanced agonism across all three receptors (Coskun et al., 2022; PMID 35985340). The structural backbone is built on a glucagon/incretin-family scaffold modified with a fatty-acid moiety that extends its circulating half-life, which in clinical research supported once-weekly subcutaneous administration. For experimental design, the high molecular weight, the lipidation, and the multi-receptor pharmacology all bear on reconstitution, binding-assay selection, and analytical confirmation. The full analytical profile — formula, mass, purity specification, and certificate-of-analysis methodology — is documented separately on the GLP3 chemistry data sheet.

The GLP3 / retatrutide research record is unusual among catalog research peptides in that it is anchored by a published industry discovery program and a sequence of registered human clinical trials, rather than by a diffuse preclinical literature. The molecule emerged from work aimed at building on the established incretin field — single-receptor GLP-1 agonists and the dual GIP/GLP-1 class — by adding glucagon-receptor agonism, on the hypothesis that engaging energy expenditure pathways alongside satiety and insulinotropic pathways could produce additive metabolic effects. The discovery-to-proof-of-concept paper characterized the peptide pharmacologically and reported the first-in-human dosing data (Coskun et al., 2022; PMID 35985340).

From there the research progressed through staged clinical evaluation. A phase 1b multiple-ascending-dose trial examined safety, tolerability, and pharmacodynamics in people with type 2 diabetes (Urva et al., 2022; PMID 36354040). Phase 2 trials followed in two populations: a 48-week trial in adults with obesity (Jastreboff et al., 2023; PMID 37366315) and a trial in adults with type 2 diabetes (Rosenstock et al., 2023; PMID 37385280). A phase 2a substudy examined participants with metabolic dysfunction-associated steatotic liver disease (Sanyal et al., 2024; PMID 38858523). More recently, a systematic review and meta-analysis pooled the randomized-trial evidence (Abouelmagd et al., 2025; PMID 40291085). This is the documented scientific history; it is presented here as research context and not as any representation that GLP3 is an approved or usable therapeutic.

The defining mechanistic feature of GLP3 is balanced single-molecule agonism at three receptors — GLP-1R, GIPR, and GCGR. The mechanisms summarized below are drawn from published pharmacology, structural biology, and clinical pharmacodynamic studies; they describe characterized receptor activity and observed physiological readouts in defined experimental and trial settings, not instructions for use.

The discovery work characterized the peptide as activating all three receptors with a balance intended to combine the glucose-lowering and satiety effects associated with GLP-1 and GIP signaling with the energy-expenditure and hepatic-lipid effects associated with glucagon-receptor signaling (Coskun et al., 2022; PMID 35985340). The structural basis for this was later resolved directly: cryo-electron microscopy structures showed how a single retatrutide molecule engages and activates the GLP-1, GIP, and glucagon receptors, providing a molecular explanation for its triple-receptor activity (Li et al., 2024; PMID 39019866).

At the pharmacodynamic level, one well-characterized peripheral effect is delayed gastric emptying. In study participants, retatrutide delayed gastric emptying, an effect consistent with GLP-1 receptor engagement and proposed by the investigators as one contributor to reduced energy intake (Urva et al., 2023; PMID 37311727). This is the kind of concrete, measurable endpoint that makes the compound tractable in mechanistic research.

The reported findings cluster into metabolic and related research domains. The summaries below report what specific studies observed in their experimental systems — including human clinical trials — and are provided as research context only; they are not claims of benefit, efficacy, or any outcome for any reader.

Weight and body-composition research is the most prominent domain. In the 48-week randomized, placebo-controlled phase 2 obesity trial, least-squares mean weight change was reported as -17.1%, -22.8%, and -24.2% across ascending dose groups versus -2.1% with placebo, with the most common adverse events being dose-related gastrointestinal events (Jastreboff et al., 2023; PMID 37366315). The pooled systematic review and meta-analysis reported significant reductions in body weight, BMI, and waist circumference versus comparators, with no statistically significant overall difference in total adverse events versus placebo (relative risk approximately 1.11) (Abouelmagd et al., 2025; PMID 40291085).

Glycemic research forms a second domain. The phase 1b multiple-ascending-dose trial in people with type 2 diabetes reported dose-dependent reductions in glycemic parameters and body weight, with a tolerability profile dominated by mild-to-moderate gastrointestinal events (Urva et al., 2022; PMID 36354040). The phase 2 type 2 diabetes trial reported dose-dependent reductions in HbA1c and body weight with a safety profile consistent with the incretin class (Rosenstock et al., 2023; PMID 37385280).

Hepatic and oncology-adjacent preclinical research round out the picture. In a phase 2a substudy of participants with metabolic dysfunction-associated steatotic liver disease (MASLD), retatrutide was associated with large reductions in liver fat content — reported up to greater than approximately 80% relative reduction at higher doses — alongside body-weight reduction (Sanyal et al., 2024; PMID 38858523). Separately, in preclinical obesity-associated tumor models, retatrutide treatment was associated with reduced tumor engraftment and tumor volume relative to controls, alongside its metabolic effects (Marathe et al., 2025; PMID 40094000). For a fuller, domain-organized treatment of these outcomes, see the GLP3 research findings page; for the underlying study-by-study citations, see the GLP3 studies library.

The questions below recur most often when investigators evaluate GLP3 for laboratory work. They are answered in a research-context, regulatory, and handling frame — not as guidance for human use, dosing, or any therapeutic or performance purpose.